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Adeno-associated virus (AAV) are the leading platform for gene therapy because of their numerous advantages. Therefore, ge-nes coding for Cas13d and the CRISPR array (region flanked by ITRs in pAAV-MCS, Fig. 5) will be delivered by AAV serotype 6, with 
tissue tropism to the airway tract (Fig. 6). 
 Moreover, CAG promoter presents better ex-pression rates in the airway tract, reducing 
off-tissue effects. 
 
• CRISPR/Cas technology is a powerful tool for nucleic acid editing and targeting. 
• The system recognizes the pathogen genome by base pairing of CRISPR-RNA (crRNA). 
• RNA-targeting Cas13d nuclease was recently discovered and has shown a robust interfe-rence activity with no off-targets in mammalian cells. 
• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a ssRNA virus. 
• Cell entry is mediated by the interaction between viral S protein and ACE2 receptor. 
• The lack of numerous antiviral strategies against COVID-19 represents an urgent need for an effective solution besides prophylaxis.  
The CRISPR array functions as a molecular memory composed of exo-
genous sequences that will be transcribed and processed, forming 
the interference complex together with Cas13d nuclease.  
Once an infection occurs, SARS-CoV-2 genome will be  
analyzed in search of complementarity and  
subsequently cleaved. 
Tissue-specific AAV AAV displaying anti-ACE2 antibody 
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An antibody fragment (scFv) against viral S protein will be fused to Cas13d in form of ribonucleoprotein complex (Cas-crRNA). The recombinant protein will be expressed from plasmid pET28b-scFv-Cas13d (Fig. 1) in an E. coli BL21 expression system. 
 
ABACAS is expected to conduct a highly specific delivery of the CRISPR system into infected cells together with the virus (Fig. 2). 
Fig. 1: Map of plasmid pET-28b-scFv-Cas13d. 
Fig. 2: Schematic representation of ABACAS delivery strategy.                Fig. 4: Schematic representation of CasACE2 delivery strategy.               
Fig. 3: Map of plasmid pET-28b-PD-Cas13d. 
Delivery of Cas13d will be conducted by the interaction between the peptidase domain (PD) of ACE2 and the spike. An E. coli BL21 expression system will be employed as well, transfecting plasmid pET-28b-PD-Cas13d (Fig. 3). 
 In addition, a neutralization of the virus is expected for viral particles with no free spike protein due to the bin-ding of ACE2 domain (Fig. 4). 
CasACE2 
Fig. 7: Schematic representation of AAV-Ab delivery strategy.  
Fig. 5: Map of plasmids involved in AAV vector production. pAAV-MCS includes the genes of inter-est, flanked by ITRs. pAAV-RC and pHelper provide trans-acting genes required for viral replica-tion. The three plasmids will be co-transfected in HEK293T cells for vector production. 
Aiming to display an antibody against ACE2 on the viral capsid, an IgG binding domain se-quence will be inserted within amino acid 587 of cap gene (Fig. 5). IgG binding molecule will bind to the antibody via its Fc region. 
 Consequently, engineered AAV will enable the delivery of the CRISPR system into cells sus-ceptible to be infected by SARS-CoV-2 (Fig. 7). 
Fig. 6: Schematic representation of AAV-6 delivery strategy. 
The following hypothesis has been set to lead the research project:  
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• Infection assays will be conducted using human alveolar epithelial cell line A549, stably expressing human ACE2 receptor. 
• A reporter nanoluciferase SARS-CoV-2 strain (SARS-CoV-2-Nluc) will be co-plated at a MOI 0.025 with different concentrations of each CRISPR-based strategy. 
• Measurment of relative luciferase signals will give an insight into the efficacy of the strategies proposed.  
CRISPR/Cas technology is able to efficiently target and neutralize 
SARS-CoV-2 as a potential treatment for COVID-19. 
To corroborate the hypothesis proposed, the overall objectives of the project are: 
• To design four CRISPR-based approaches able to combat SARS-CoV-2. 
• To successfully produce the pertinent constructs. 
• To compare the strategies developed in terms of efficacy. 
• Absent or minimal cytotoxicity effects. 
• Reduction of Nluc signal in a dose-
dependent manner. 
• Dissemination of the results. 
• Validation via in vivo and subsequent clinical assays. 
• Define therapeutic indications. 
• Further studies about both CRISPR/Cas13d and SARS-CoV-2 are required. Initial discussion of the optimal strategy from a comprehensive view. 
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